ClinVar Miner

Submissions for variant NM_000138.5(FBN1):c.2168A>C (p.Asp723Ala)

dbSNP: rs137854463
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
MGZ Medical Genetics Center RCV000017895 SCV002579946 likely pathogenic Marfan syndrome 2022-05-11 criteria provided, single submitter clinical testing
Ambry Genetics RCV002426510 SCV002729213 likely pathogenic Familial thoracic aortic aneurysm and aortic dissection 2021-03-26 criteria provided, single submitter clinical testing The p.D723A variant (also known as c.2168A>C), located in coding exon 18 of the FBN1 gene, results from an A to C substitution at nucleotide position 2168. This variant impacts the first base pair of coding exon 18. The aspartic acid at codon 723 is replaced by alanine, an amino acid with dissimilar properties, and is located in the cbEGF-like #7 domain. This variant was detected as a de novo heterozygous variant in an individual who met clinical criteria for Marfan syndrome (Dietz HC et al. Genomics, 1993 Aug;17:468-75). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic.
Labcorp Genetics (formerly Invitae), Labcorp RCV003764583 SCV004570995 pathogenic Marfan syndrome; Familial thoracic aortic aneurysm and aortic dissection 2023-10-04 criteria provided, single submitter clinical testing This sequence change replaces aspartic acid, which is acidic and polar, with alanine, which is neutral and non-polar, at codon 723 of the FBN1 protein (p.Asp723Ala). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with Marfan syndrome (PMID: 8406497). In at least one individual the variant was observed to be de novo. This variant is also known as D-176A. ClinVar contains an entry for this variant (Variation ID: 16433). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. This variant disrupts the p.Asp723 amino acid residue in FBN1. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 12203987). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.
OMIM RCV000017895 SCV000038174 pathogenic Marfan syndrome 1992-05-01 no assertion criteria provided literature only

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.